Chimeric C3-CVF Proteins for Stable Complement Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-complementary agents fail to effectively inhibit unwanted complement activation in diseases, as Cobra Venom Factor (CVF) depletes serum complement but is immunogenic and not suitable for human application, necessitating a non-immunogenic alternative that mimics CVF's complement-depleting function.
Innovation Solution
Development of chimeric human complement C3 proteins with substitutions from Cobra Venom Factor (CVF) to create molecules that form stable convertases with enhanced stability and resistance to regulatory proteins, reducing immunogenicity while maintaining complement-depleting activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Cobra Venom Factor (CVF) is used to deplete serum complement, then complement-depleting function is achieved, but immunogenicity increases making it unsuitable for human application
Solution Approach 1:
The patent creates chimeric proteins by combining CVF domains with human C3 domains. Specifically, the N-terminal domain of CVF (which contains the complement-depleting function) is fused to the C-terminal domain of human C3. This composite structure allows the protein to maintain CVF's ability to form stable convertases and deplete complement, while the human C3 portion reduces immunogenicity by making the molecule more similar to endogenous human proteins.
2Reliability
If C3b,Bb convertase is formed for complement activation, then C3 and C5 cleavage occurs, but the enzyme exhibits short half-life and is susceptible to regulatory protein inactivation
Solution Approach 1:
The patent introduces CVF-specific domains into the C3 molecule at specific locations. The N-terminal domain of CVF is incorporated into the chimera, which locally confers the stability and regulatory protein resistance characteristics of CVF to the otherwise human C3 molecule. This localized introduction of foreign domains allows the protein to gain enhanced stability without requiring complete replacement of the human sequence.
Solution Approach 2:
The chimeric structure fundamentally changes the kinetic parameters of the convertase. The CVF-containing convertase exhibits a half-life of approximately 7 hours at 37°C, compared to only 1.5 minutes for the native C3b,Bb convertase. This parameter change transforms the enzyme from a transient activator to a persistent one, enabling continuous complement activation and eventual depletion.
3Object-affected harmful factors
If native C3 is used for complement activation, then low immunogenicity is maintained, but complement-depleting function is insufficient due to rapid convertase decay
Solution Approach 1:
The patent merges the complementary strengths of two different proteins: the low immunogenicity of human C3 and the complement-depleting capability of CVF. By fusing these two molecules into a single chimeric protein, the invention creates a molecule that inherits the favorable properties of both parents, achieving a balance between safety (low immunogenicity) and efficacy (complement depletion).
Data Source
AI summary
A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics.